Corona Remedies Fair Value
Corona Remedies fair value. Corona Remedies (CORONA) average fair value is ₹430.27 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹2034.2 (-78.85%), fair value range ₹122.46–₹1592.31. For live price and a broader fundamental view, visit CORONA share price screener.
Fair Value Analysis Export
CORONA Fair Value vs Current Price — Valuation Summary
CORONA average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). Explore CORONA intrinsic value to estimate fundamental worth using multiple valuation models.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
CORONA Fair Value Analysis — Data Sources & Coverage
Corona Remedies financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year. Check Corona Remedies networth to track the company's total market size over time.
Available Data Sources: Financial statements, dividend history, balance sheet data , sector comparisons.
Data Currency: Financial data is from the current year (2026).
CORONA vs Healthcare Sector Peers — P/E, P/B & Market Cap
Corona Remedies P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Emcure Pharmaceuticals | EMCURE | 35.85 | 7.38 | ₹37,156 |
| Syngene International | SYNGENE | 68.69 | 3.13 | ₹15,000 |
| Sat Kartar Life | SATKARTAR | 16.56 | 4.14 | ₹307 |
| Divis Laboratories | DIVISLAB | 87.22 | 15.22 | ₹253,522 |
| Aurobindo Pharma | AUROPHARMA | 25.97 | 2.54 | ₹96,479 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.